Generics for Xarelto with sales of ₩60 billion are com

Sixty-nine items from 23 generics

Chong Kun Dang to push ahead with the launch of Riroxia before patent expires

Competition of generic products is in full swing in the new oral anticoagulant (NOAC) market of Rivaroxaban ingredients worth 60 billion won a year.

 

With more than 20 companies' generics pouring in in earnest since the fourth quarter of last year, Chong Kun Dang seems to be one step ahead.

 

In the pharmaceutical industry, it is analyzed that this is the result of Chong Kun Dang's preoccupation with the market by pushing ahead with the release of generic before the patent expires.

 

◆Expanding the influence of generics for Xarelto According to UBIST, a pharmaceutical market research firm, on the 23rd, the market size of outpatient prescriptions for Rivaroxaban-based anticoagulants in the first quarter is estimated to be 16.8 billion won.

 

It increased by 13% compared to 14.8 billion won in the first quarter of last year.

 

It is analyzed that the overall market size has also expanded with the addition of generic.

 

During the period, the prescription amount of Xarelto, an original product, fell 4% from 14.8 billion won to 14.2 billion won.

 

Analysts say that growth has decreased due to the release of generic.

 

Bayer has delayed the reduction of drug prices due to generic registration through administrative litigation.

 

Generic posted a total of 2.6 billion won in prescription performance in the first quarter of this year.

 

Since the first generics came out in the second quarter of last year, they are gradually increasing their influence.

 

As of the first quarter of this year, the market share of Rivaroxaban reached 16%.

 

◆Chong Kun Dang's Rivaroxaban ranked first among generics While generic is gradually expanding its influence, Chong Kun Dang's Rivaroxaban is located at the highest position among generic products.

 

The first quarter prescription is 600 million won.

 

This is interpreted as the result of Chong Kun Dang's preoccupation with the market by pushing ahead with the release of generic before the patent expires.

 

Chong Kun Dang released Riroxia as generics for Xarelto in May last year.

 

At that time, it was five months before the expiration of the Xarelto patent (October 2021).

 

In the pharmaceutical industry, it is interpreted as Chong Kun Dang's winning move to dominate the Xarelto's generic market.

 

Based on the victory of the Eliquis patent dispute, domestic companies have sold generics for Eliquis since July 2019.

 

Sales of generics for Eliquis were suspended in April last year when the Supreme Court overturned the first and second trials and sided with the original company.

 

Chong Kun Dang was the most active in promoting generics for Eliquis, causing great damage.

 

In this situation, it was quickly replaced by generics for Xarelto, which has only a few days left before the expiration of the patent.

 

Chong Kun Dang's winning move is somewhat correct.

 

The cumulative prescription recorded by Chong Kun Dang over the past 11 months is 1.8 billion won.

 

It is higher than the prescription performance (1 billion won) for 11 months after the release of generics for Eliquis.

 

◆ Since October last year, market competition is expected to heat up The pharmaceutical industry predicts that competition between generics for Xarelto will intensify in the future.

 

Except for Chong Kun Dang, other generic companies joined the market in earnest in the fourth quarter of last year.

 

Since October last year, when the Xarelto patent expired, 22 companies, including Samjin Pharmaceutical and Hanmi Pharmaceutical, have poured out 66 items of generics for Xarelto.

 

It was five months after Chong Kun Dang entered the market.

 

They are rapidly expanding their influence.

 

Excluding Riroxia, the total prescription amount of generic for Xarelto increased 2.5 times from 400 million won in the fourth quarter of last year to 1 billion won in the first quarter of this year.

 

After the second quarter, competition for generic is expected to intensify.

 

This is because more than 20 companies have yet to officially release their products after receiving Xarelto permission and benefits.

 

Generics are predicting aggressive promotions with price competitiveness.

 

Based on Rivaroxaban 10mg, the upper limit price of Riroxia is 1,312 won.

 

Most of the remaining companies listed at 1,115 won.

 

Samjin Pharmaceutical's generic costs 770 won, and Ildong Pharmaceutical's generic costs 760 won.